Reading NXTC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NXTC free→Reading NXTC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NXTC free→QuarterlyIQ Insights · NXTC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On May 7, 2026, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Results of Operations and Financial Condition On March 5, 2026, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the ”Exchange Act”), or ot…
are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to statements related to our cash runway and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statem…
Results of Operations and Financial Condition On January 23, 2026, NextCure, Inc. (the “Company”) issued a press release announcing preliminary results that as of December 31, 2025, it had approximately $41.8 million in cash, cash equivalents and marketable securities. The Company expects current financial resources to be sufficient to fund planned operating expenses and capital expenditures into the first half of 2027. Because the Company’s consolidated financial statements for the year…
Other Events. On December 19, 2025, NextCure, Inc. (the “Company”) entered into an at the market offering agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $14,500,000 of its common stock, $0.001 par value per share (the “Common Stock”), through the Agent. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including, among o…
Entry into a Material Definitive Agreement Securities Purchase Agreement On November 12, 2025, NextCure, Inc. (“NextCure” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) for a private placement (the “Offering”) of an aggregate of (i) 708,428 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at…
Unregistered Sales of Equity Securities To the extent required by Form 8-K, the disclosures in
Results of Operations and Financial Condition On November 5, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The company is furnishing a copy of the press release, which is attached hereto as exhibit 99.1. The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 21, 2025, Solomon Langermann, Ph.D., resigned from his position as Chief Scientific Officer of NextCure, Inc. (the “Company”), effective September 1, 2025. Dr. Langermann’s decision to resign was not the result of any disagreement with the Company or any matter relating to the operations, policies or practices of the Company. The Company…
Results of Operations and Financial Condition On August 7, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Material Modification to Rights of Security Holders The information set forth in
Regulation FD Disclosure On June 16, 2025, the Company issued a press release announcing the Licensing Agreement and the Private Placement and made publicly available a corporate presentation that included information on SIM0505. A copy of the press release and the data presentation are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein. The exhibits furnished under
Unregistered Sales of Equity Securities To the extent required by Form 8-K, the disclosures in
Entry into a Material Definitive Agreement Licensing Agreement On June 13, 2025, NextCure, Inc. (“NextCure” or the “Company”) entered into a License Agreement (the “Licensing Agreement”) with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (“Zaiming”), a biopharmaceutical company based in China. Pursuant to the Licensing Agreement, the Company obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaimin…
Results of Operations and Financial Condition On May 1, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.